In conclusion, our study including more than 600 patients with advanced cancer treated with PD-1 or PD-L1 inhibitors in a real-world setting, supports the results from randomized trials demonstrating a favorable toxicity profile for PD-L1 inhibitors versus PD-1 inhibitors. The gene discussed is CD274; the disease is cancer.